PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery

Company Continues to Expect that the Last Patient Will be Enrolled in the Second Quarter of 2022, Followed by Top-Line Results Two Months Thereafter PETAH TIKVA, Israel , Nov. 18, 2021 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical